77181-69-2 Usage
Description
Sorivudine is an orally-active antiviral nucleoside analog with potent and selective activity against herpes simplex virus type-1 (HSV-1) and varicella-zoster virus (VZV). It is used to synthesize antiviral compounds and treat diseases of viral etiology.
Uses
Used in Antiviral Applications:
Sorivudine is used as an antiviral agent for the treatment of diseases caused by herpes simplex virus type-1 (HSV-1) and varicella-zoster virus (VZV). It demonstrates significant antiviral activity, particularly in cutaneous model infections of mice with HSV-1, where oral administration at a dose of 20 mg/kg resulted in a substantial increase in the survival rate.
Used in Topical Treatment:
Sorivudine is used as a topical treatment for cutaneous HSV-1 infection, including immunocompromised patients. A 5% sorivudine cream has been found useful in managing such infections.
Used in Pharmaceutical Industry:
Sorivudine is used as a key component in the synthesis of antiviral compounds, contributing to the development of new drugs for the treatment of viral diseases.
Precaution:
Sorivudine's metabolite inhibits the enzyme responsible for pyrimidine catabolism. Therefore, it is crucial not to use sorivudine in combination with fluorouracil drugs to avoid hematological disorders.
Brand Names:
Bravavir (Bristol-Myers Squibb); Usevir.
Originator
Yamasa Shoyu (Japan)
Check Digit Verification of cas no
The CAS Registry Mumber 77181-69-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,7,1,8 and 1 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 77181-69:
(7*7)+(6*7)+(5*1)+(4*8)+(3*1)+(2*6)+(1*9)=152
152 % 10 = 2
So 77181-69-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H13BrN2O6/c12-2-1-5-3-14(11(19)13-9(5)18)10-8(17)7(16)6(4-15)20-10/h1-3,6-8,10,15-17H,4H2,(H,13,18,19)/b2-1+/t6-,7-,8+,10-/m1/s1
77181-69-2Relevant articles and documents
NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY
-
Page/Page column 20, (2010/09/17)
The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytostatic treatment of a cancer patient.
Facile access to 2′-O-acyl prodrugs of 1- (β-D-arabinofuranosyl)-5(E)-(2-bromovinyl)uracil (BVAraU) via regioselective esterase-catalyzed hydrolysis of 2′ 3′, 5′-triesters
Baraldi, Pier G.,Bazzanini, Rita,Manfredini, Stefano,Simoni, Daniele,Robins, Morris J.
, p. 3177 - 3180 (2007/10/02)
Treatment of 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl) -5-[2-(trimethylsilyl)-vinyl]uracil (3) with pyridinium bromide perbromide and deacetylation gave BVAraU (2). Pig liver esterase (EC 3.1.1.1) catalysed the regioselective hydrolysis of 1-
